(Q54152292)

English

In vitro activity of clarithromycin alone and in combination with ciprofloxacin or levofloxacin against Legionella spp.: enhanced effect by the addition of the metabolite 14-hydroxy clarithromycin.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9401809

In vitro activity of clarithromycin alone and in combination with ciprofloxacin or levofloxacin against Legionella spp.: enhanced effect by the addition of the metabolite 14-hydroxy clarithromycin. (English)

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9401809

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Martin SJ

1

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9401809

Pendland SL

2

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9401809

Chen C

3

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9401809

Schreckenberger PC

4

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9401809

Danziger LH

5

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9401809

publication date

1 November 1997

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9401809

Diagnostic Microbiology and Infectious Disease

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9401809

29

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9401809

3

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9401809

167-171

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9401809

Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clarithromycin pharmacokinetics in healthy young and elderly volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Legionnaires' disease: description of an epidemic of pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of disk susceptibility testing of cefotaxime/desacetylcefotaxime

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A review of cephalosporin metabolism: a lesson to be learned for future chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The antimicrobial activity of A-56268 (TE-031) and roxithromycin (RU965) against Legionella using broth microdilution method

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of clarithromycin (TE-031, A-67268) and 14OH-clarithromycin alone and in combination against Legionella species

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A new macrolide, TE-031 (A-56268), in treatment of experimental Legionnaires' disease

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The in-vitro activity and disc susceptibility testing of clarithromycin and its 14-hydroxy metabolite

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of metronidazole and its hydroxy metabolite against Bacteroides spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

In-vitro activity of six intracellular antibiotics against Legionella pneumophila strains of human and environmental origin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of legionellae in acute infections of the lower respiratory tract

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The incidence of legionella pneumonia: a 1-year prospective study in a large community hospital.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergistic interaction of cefotaxime and its metabolite desacetylcefotaxime demonstrated by drug-impregnated disks.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Legionnaires' Disease: Clinical Features of the Epidemic in Philadelphia

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2981806-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0732-8893(97)81806-8

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9401809

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9401809

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54152292&oldid=1561759406"